Stanley Erck, Novavax CEO (Andrew Harnik, AP Images)

No­vavax shares dive on yet an­oth­er stum­ble in the hunt for an EUA, with FDA de­lay as US paus­es fund­ing

Rack up an­oth­er de­lay for No­vavax $NVAX on the cru­cial EUA front.

The biotech’s Q2 re­view dropped af­ter the mar­ket close on Thurs­day, and with it came the news that their re­quest for an emer­gency use ap­proval of their Covid-19 vac­cine at the FDA — al­ready pushed back sev­er­al times — would once again slip back an­oth­er quar­ter, this time to Q4.

Com­pa­ny ex­ecs led by CEO Stan Er­ck down­played the de­lay. But ear­ly Fri­day The New York Times flagged No­vavax’s SEC fil­ing, high­light­ing:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.